Matsuda Masaru
See Remarks · 18 insider transactions on file
All transactions
| Date | Ticker | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-05-04 | ARQT | Arcutis Biotherapeutics, Inc. | Sale | 7,372 | $23.27 | $171,543.49 | filing |
| 2026-05-04 | ARQT | Arcutis Biotherapeutics, Inc. | Sale | 884 | $23.61 | $20,871.77 | filing |
| 2026-03-02 | ARQT | Arcutis Biotherapeutics, Inc. | Sale | 6,553 | $25.16 | $164,876.10 | filing |
| 2026-03-02 | ARQT | Arcutis Biotherapeutics, Inc. | Sale | 1,987 | $25.70 | $51,065.90 | filing |
| 2026-03-02 | ARQT | Arcutis Biotherapeutics, Inc. | Sale | 193 | $25.91 | $5,001.38 | filing |
| 2026-02-27 | ARQT | Arcutis Biotherapeutics, Inc. | Sale | 3,325 | $27.95 | $92,933.75 | filing |
| 2026-02-27 | ARQT | Arcutis Biotherapeutics, Inc. | Award | 37,000 | $0.00 | $0.00 | filing |
| 2026-02-02 | ARQT | Arcutis Biotherapeutics, Inc. | Sale | 19,379 | $25.24 | $489,125.96 | filing |
| 2026-02-02 | ARQT | Arcutis Biotherapeutics, Inc. | Sale | 8,562 | $24.97 | $213,793.14 | filing |
| 2026-02-02 | ARQT | Arcutis Biotherapeutics, Inc. | Sale | 7,983 | $25.50 | $203,553.73 | filing |
| 2026-02-02 | ARQT | Arcutis Biotherapeutics, Inc. | Sale | 4,714 | $25.63 | $120,819.82 | filing |
| 2025-12-01 | ARQT | Arcutis Biotherapeutics, Inc. | Sale | 1,657 | $30.23 | $50,091.11 | filing |
| 2025-11-19 | ARQT | Arcutis Biotherapeutics, Inc. | Sale | 1,561 | $28.50 | $44,488.50 | filing |
| 2025-11-19 | ARQT | Arcutis Biotherapeutics, Inc. | Sale | 989 | $27.95 | $27,646.60 | filing |
| 2025-11-03 | ARQT | Arcutis Biotherapeutics, Inc. | Sale | 7,165 | $24.71 | $177,063.63 | filing |
| 2025-11-03 | ARQT | Arcutis Biotherapeutics, Inc. | Sale | 43 | $25.40 | $1,092.14 | filing |
| 2025-09-04 | ARQT | Arcutis Biotherapeutics, Inc. | Sale | 36,130 | $16.16 | $583,716.28 | filing |
| 2025-08-04 | ARQT | Arcutis Biotherapeutics, Inc. | Sale | 6,330 | $14.33 | $90,687.38 | filing |
Insider transactions from SEC Form 4 filings via EDGAR. Names appear as filed and aren't normalized across issuers.